RxDoctor Payments Data

Caroline Mathew, MD

Internal Medicine · Flint, MINPI 1710988480

Payments from drug & device makers

$285in general payments, 2019–2025

Across 18 payments — averaging $15.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$71
  • Lilly USA, LLC$51
  • Novo Nordisk$36
  • Amgen$35
  • AstraZeneca$34
  • GSK$21
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$27195%
  • Education$145%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$285 in reported general payments places this provider in the 55th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$126,587
Medicare patients
224
Services billed
3,305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide166$243,356
EliquisApixaban219$192,761
MounjaroTirzepatide97$130,105
OzempicSemaglutide87$123,402
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$53,298
XareltoRivaroxaban40$40,484
TradjentaLinagliptin43$31,303
JanuviaSitagliptin Phosphate37$30,605
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate48$22,375
EntrestoSacubitril/Valsartan15$21,575
RybelsusSemaglutide19$18,241
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro18$15,859
LinzessLinaclotide22$15,415
SymbicortBudesonide/Formoterol Fumarate39$14,855
Lantus SolostarInsulin Glargine,hum.Rec.Anlog79$14,814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$51$373,461263 claims
Novo NordiskOzempic, Rybelsus$36$141,643106 claims
GSKTrelegy Ellipta$21$53,29860 claims
AstraZenecaSymbicort, Farxiga, Brilinta$34$31,10166 claims
AbbVieLinzess$71$15,41522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Flint

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →